US04537Y1091 - Common Stock - Premarket: 0.5 -0.01 (-1.96%)
Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021 Preliminary results...
Provides clinical validation for the use of OvaWatchSM in the assessment of ovarian cancer risk for suspected benign or indeterminate adnexal masses ...
Expanded Medicare coverage for multi-marker testing, including Ova1Plus® and OvaWatchSM, through the 2023 Omnibus Spending Bill Granted a new PLA Code...
AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on...
Increased year-over-year product revenue by 26% to $2.0 million and year-over-year product volume by 29% to 5,524 units Reconfirmed fourth quarter launch...
AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced...
Data demonstrates the accuracy of Aspira’s multivariate assessment test OVERA in a non-White population and concludes use of OVERA to be better than CA-125...
AUSTIN, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women’s health company...
KOL Event to take place on Wednesday, August 24th at 12:00pm ET...
Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber...
AUSTIN, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on...
Seasoned Directors further strengthen Board with decades of industry and leadership experience...
Paper published in the June online issue of JCO Clinical Cancer Informatics...